Zacks Research Weighs in on Revvity, Inc.’s FY2024 Earnings (NYSE:RVTY)

Revvity, Inc. (NYSE:RVTY) – Analysts at Zacks Research boosted their FY2024 earnings per share estimates for shares of Revvity in a research report issued to clients and investors on Monday, May 20th. Zacks Research analyst I. Bandyopadhyay now expects that the company will earn $4.64 per share for the year, up from their prior estimate of $4.62. The consensus estimate for Revvity’s current full-year earnings is $4.66 per share. Zacks Research also issued estimates for Revvity’s Q4 2024 earnings at $1.35 EPS, Q1 2025 earnings at $1.12 EPS, Q3 2025 earnings at $1.32 EPS, Q1 2026 earnings at $1.31 EPS and FY2026 earnings at $5.67 EPS.

Revvity (NYSE:RVTY) last posted its quarterly earnings results on Monday, April 29th. The company reported $0.98 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.94 by $0.04. The firm had revenue of $649.90 million for the quarter, compared to analysts’ expectations of $646.83 million. Revvity had a return on equity of 7.37% and a net margin of 5.49%. The company’s revenue for the quarter was down 3.7% compared to the same quarter last year. During the same period in the prior year, the business earned $1.01 EPS.

Other equities analysts have also recently issued reports about the company. Robert W. Baird increased their price target on Revvity from $126.00 to $127.00 and gave the stock an “outperform” rating in a report on Tuesday, April 30th. Stifel Nicolaus increased their target price on Revvity from $95.00 to $110.00 and gave the stock a “hold” rating in a report on Friday, February 2nd. Barclays increased their target price on Revvity from $92.00 to $105.00 and gave the stock an “equal weight” rating in a report on Thursday, January 25th. Raymond James increased their target price on Revvity from $106.00 to $127.00 and gave the stock an “outperform” rating in a report on Friday, February 2nd. Finally, KeyCorp increased their target price on Revvity from $110.00 to $126.00 and gave the stock an “overweight” rating in a report on Friday, February 2nd. Six equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, Revvity currently has an average rating of “Moderate Buy” and an average target price of $118.17.

Revvity Price Performance

Revvity stock opened at $112.67 on Tuesday. The stock has a market capitalization of $13.90 billion, a price-to-earnings ratio of 93.12, a PEG ratio of 2.91 and a beta of 1.09. Revvity has a 52-week low of $79.50 and a 52-week high of $131.96. The stock’s 50 day moving average price is $104.43 and its two-hundred day moving average price is $102.43. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.92 and a current ratio of 2.23.

Institutional Investors Weigh In On Revvity

Institutional investors and hedge funds have recently bought and sold shares of the stock. Parkside Financial Bank & Trust purchased a new stake in Revvity in the 4th quarter valued at $25,000. Gladius Capital Management LP increased its position in shares of Revvity by 84.1% during the 3rd quarter. Gladius Capital Management LP now owns 232 shares of the company’s stock valued at $26,000 after purchasing an additional 106 shares during the last quarter. Benjamin F. Edwards & Company Inc. purchased a new stake in shares of Revvity during the 4th quarter valued at $27,000. CENTRAL TRUST Co purchased a new stake in shares of Revvity during the 4th quarter valued at $27,000. Finally, ORG Partners LLC purchased a new stake in shares of Revvity during the 4th quarter valued at $32,000. 86.65% of the stock is owned by hedge funds and other institutional investors.

Revvity Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, August 9th. Investors of record on Friday, July 19th will be given a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a yield of 0.25%. The ex-dividend date is Friday, July 19th. Revvity’s payout ratio is currently 23.14%.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.